Friday October 20th 2017

Teva asks Supreme Court to review Copaxone ruling

Teva Pharmaceuticals has filed a petition with the U.S. Supreme Court asking for a review of a lower court’s ruling that invalidated key patents for the company’s multiple sclerosis drug Copaxone. A Teva spokeswoman confirmed the filing, but said the company would have no additional comment on the matter. Copaxone, which generated about $3.8 billion in sales for Teva (NYSE: TEVA) last year, is scheduled to lose patent protect in May. Based in Israel, Teva has its North American headquarters… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)

See the original article here: 

Teva asks Supreme Court to review Copaxone ruling

Leave a Comment

More from category

OHSU’s Robertson on coming to grips with his diagnosis
OHSU’s Robertson on coming to grips with his diagnosis

After learning that he has multiple sclerosis, Dr. Joe Robertson was in denial. Then he realized there was no other [Read More]

Concussion in teens increase risk of multiple sclerosis
Concussion in teens increase risk of multiple sclerosis

Researchers from Orebro University in Sweden studied the connection between concussions and multiple sclerosis. They [Read More]

Phys Ed: Concussions in Teenagers Tied to Multiple Sclerosis Risk
Phys Ed: Concussions in Teenagers Tied to Multiple Sclerosis Risk

A large-scale new study found that concussions in adolescents can increase the risk of later developing multiple [Read More]

Multiple sclerosis: Oligodendrocytes from stemmcells
Multiple sclerosis: Oligodendrocytes from stemmcells

(Heinrich-Heine University Duesseldorf) A scientific collaboration between stem cell researchers of the [Read More]

Global Experts Publish Recommendations for Overcoming Challenges to Improve Clinical Trials in Progr
Global Experts Publish Recommendations for Overcoming Challenges to Improve Clinical Trials in Progr

/About-the-Society/News/Global-Experts-Publish-Recommendations-for-Overcom [Read More]